Vaccine developer SK Bio heats up Korean market with IPO
myskin - stock.adobe.com
SK Bioscience has priced its IPO at the top of the marketed range, raising W1.49tr ($1.32bn) from South Korea’s largest listing in four years.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: